US Life Expectancy Reaches New High

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

WASHINGTON-Life expectancy in the United States reached 76.9 years in 2000, a record high, according to preliminary figures released by the Centers for Disease Control and Prevention. CDC attributed the increase in part to continuing declines in the aged-adjusted death rates for cancer and heart disease, the nation’s two leading causes of death.

WASHINGTON—Life expectancy in the United States reached 76.9 years in 2000, a record high, according to preliminary figures released by the Centers for Disease Control and Prevention. CDC attributed the increase in part to continuing declines in the aged-adjusted death rates for cancer and heart disease, the nation’s two leading causes of death.

Mortality from HIV infection decreased 3.7% last year, its fifth consecutive year of decline. Adjusted death rates also fell for other leading causes of death: homicide, suicide, accidents or "unintentional injuries," strokes, diabetes, chronic lower respiratory diseases, and chronic liver disease and cirrhosis.

Mortality increased for Alzheimer’s disease, influenza, pneumonia, kidney disease, hypertension, septicemia, and pneumonitis due to solids and liquids, an age-related illness that made the top 15 causes of death for the first time.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video